Skip to content
TrialScanner

NCT07517198

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Phase 1RecruitingRXRXLead

Registry record

Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Conditions
Solid Tumor; Small Cell Lung Cancer (SCLC); High Grade Neuroendocrine Cancer; Small Cell Carcinomas of Non-lung Origin; Non-small Cell Lung Cancer (NSCLC)
Primary completion
Mar 2029Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT07517198 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT07517198: Dose Determining Study of... | TrialScanner